REPORT HIGHLIGHT
Antiviral Drugs Market size was valued at USD 68,430.4 Million in 2022, expanding at a CAGR of -2.1% from 2023 to 2030.
Antiviral drugs are prescriptions that work by preventing viruses from replicating within the cells that they infect. These medications either stop the virus from entering the host cell or disrupt essential enzymes or proteins needed for viral reproduction. They are designed to target certain viruses or virus species.
Antiviral Drugs Market- Market Dynamics
Increasing prevalence of viral disorders and development in antiviral medicines is to propel market demand
Over the forecast period, rising awareness and availability of different vaccinations for viral infections and the rising prevalence of viral diseases, which has led to the launch of generic versions of antiviral medications, are projected to positively affect the market's growth. The WHO estimates that 325 million individuals worldwide have hepatitis infection, and of those, about 71 million have chronic infection with the Hepatitis C virus (HCV). Furthermore, the U.S. Department of Health and Human Services calculated that 850,000 people in the nation are infected with hepatitis B, and 2.4 million people with hepatitis C. Therefore, it is expected that the demand for antiviral medications will rise internationally as the number of patients grows.
Antiviral Drugs Market- Key Insights
- As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around -2.1% over the forecast period (2023-2030)
- Based on Type segmentation, synthetic branded segment was predicted to show maximum market share in the year 2022, owing to high adoption of branded therapeutics in viral treatment.
- Based on Application segmentation, HIV segment was the leading type in 2022, mainly due to increasing demand for antiretroviral therapy medications.
- Based on Distribution Channel segmentation, hospital pharmacy was the leading type in 2022, mainly due to hospitalization treatment needs.
- On the basis of region, North America was the leading revenue generator in 2022, owing to availability of technologically advanced production facilities.
Antiviral Drugs Market- Segmentation Analysis:
- The Global Antiviral Drugs Market is segmented on the basis of Type, Application, Distribution Channel, and Region.
- The market is divided into four categories based on Type: branded and generics. The branded segment dominates the market. The technology development, growing emphasis on novel therapeutics are likely to contribute to market growth.
- The market is divided into five categories based on Application: HIV, hepatitis, herpes, influenza, and others. The HIV segment dominates the market and is likely to maintain its dominance during the forecast period. Antiviral drugs play crucial role in treatment of HIV viral infections with therapeutic medications.
- The market is divided into three categories based on Distribution Channel: hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy dominates the market and is likely to maintain its dominance during the forecast period. Online pharmacy is gaining more traction at fast pace with online e-commerce benefits.
Antiviral Drugs Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Antiviral Drugs Market- Competitive Landscape:
To increase their market share, businesses are engaging in strategic initiatives like joint ventures, mergers, acquisitions, clinical trials, and strategic agreements for the purpose of expanding their product line. Industry participants are also focusing on product releases for food allergies and global expansion to maintain their position in the global market. The worldwide antiviral drugs market has been further impacted by supportive FDA, U.S., and government collaborations. For instance, in December 2021, Merck collaborated with Ridgeback Biotherapeutics and established FDA approval for molnupiravir, an oral antiviral agent for backup use to treat low to high COVID-19.
Recent Developments:
In March 2022, Scripps Research, a research & technology and drug discovery organization, and AbbVie Inc. established a strategic collaboration to investigate novel drugs, to provide immediate treatments for COVID-19.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTIVIRAL DRUGS MARKET KEY PLAYERS
- F. Hoffmann-La Roche Ltd.
- GSK plc.
- AbbVie, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Ridgeback Biotherapeutics
- Aurobindo Pharm
- Dr. Reddy's Laboratories Ltd.
- Zydus Pharmaceuticals
- SIGA Technologies
- Pfizer Inc.
- NAVINTA LLC
- Sun Pharma
- Others
GLOBAL ANTIVIRAL DRUGS MARKET, BY TYPE
GLOBAL ANTIVIRAL DRUGS MARKET, BY APPLICATION
- HIV
- Hepatitis
- Herpes
- Influenza
- Others
GLOBAL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL ANTIVIRAL DRUGS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA